(Q48020812)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

title

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

Vassiliki Papadimitrakopoulou

29 March 2020

17

object named as

Vassiliki A Papadimitrakopoulou

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

0 references

Tony S Mok

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Yi-Long Wu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Myung-Ju Ahn

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Hye R Kim

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Suresh S Ramalingam

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Frances A Shepherd

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Yong He

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Hiroaki Akamatsu

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Willemijn S M E Theelen

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Chee K Lee

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Martin Sebastian

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Alison Templeton

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Helen Mann

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Marcelo Marotti

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Serban Ghiorghiu

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

AURA3 Investigators

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

language of work or name

English

0 references

publication date

6 December 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

The New England Journal of Medicine

29 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

volume

376

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

page(s)

629-640

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

29 March 2020

cites work

1 reference

12 December 2020

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

1 reference

12 December 2020

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

12 December 2020

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

12 December 2020

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation

1 reference

12 December 2020

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

12 December 2020

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

1 reference

12 December 2020

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

12 December 2020

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

12 December 2020

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

12 December 2020

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

1 reference

12 December 2020

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

12 December 2020

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

12 December 2020

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

1 reference

12 December 2020

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

1 reference

12 December 2020

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

1 reference

12 December 2020

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

1 reference

12 December 2020

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

1 reference

12 December 2020

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

1 reference

12 December 2020

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.

1 reference

12 December 2020

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1612674

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27959700%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1 reference